The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Nearly 85% of GLP-1 users hit a weight loss plateau, but experts say simple tweaks can restart progress. From optimizing doses to boosting protein and walking after meals, discover how to turbocharge Ozempic, Wegovy, or Mounjaro. Avoid quitting—stopping leads to rapid regain, per Oxford research.
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
With obesity affecting a significant portion of the UK population, weight loss injections have gained popularity but often come with risks and rebound effects. Experts highlight that natural ingredients like Glucomannan and Resveratrol can support weight loss through diet and lifestyle changes, mimicking hormonal benefits without drawbacks. This approach offers a safer alternative for appetite control and metabolic health.
A comprehensive analysis published in The BMJ reveals that discontinuing weight loss drugs leads to an average monthly regain of 0.4 kg, with full weight and cardiometabolic risks returning within two years. This regain occurs nearly four times faster than after dietary and lifestyle interventions, raising questions about the drugs' long-term effectiveness. Experts emphasize combining medications with healthy habits for sustainable obesity control.
GLP-1 injectable treatments have surged in popularity in India, prompting medical professionals to emphasize comprehensive diagnostic evaluations before initiating therapy. Key assessments cover metabolic health, organ function, and specific risks to guarantee patient safety. This approach underscores the importance of medical oversight for these potent medications.
A novel CMS demonstration program seeks to broaden access to GLP-1 receptor agonists for individuals in Medicare Part D and Medicaid, aiming to address weight management and metabolic health. While it promises negotiations with manufacturers for reduced prices, experts remain skeptical about its widespread effectiveness. The initiative builds on prior drug pricing efforts and includes provisions for lifestyle support, with launch timelines set for 2026.
Eli Lilly's Mounjaro, a groundbreaking GLP-1 agonist, is altering the landscape of obesity and diabetes management in the US. This article explores its market success, addresses key patient challenges, and delves into the investment implications for LLY stock, highlighting growth drivers and potential risks.
A recent article highlights key considerations for individuals seeking qualified medical weight loss providers, particularly concerning GLP-1 treatments. It stresses the importance of thorough evaluations, ongoing monitoring, and comprehensive plans for effective and sustainable weight management.
Discover the leading semaglutide choices for weight loss in 2026. This article examines FDA-approved GLP-1 programs, safety protocols, access methods, and the structure of MEDVi's online weight loss platform. As medical weight loss evolves, understanding the best options is crucial.
